Cardiometabolic Disorders

Top Story

AMPK activator reduces glucose level in type 2 diabetes in phase 2a trial

November 18, 2017

A novel AMP-activated protein kinase activator showed glucose reduction and decreased cardiovascular risk factors in people with type 2 diabetes in a phase 2a trial, according to a press release from the drug’s developer.

The first-in-class drug (O304, Betagenon/Baltic Bio) activates AMP-activated protein kinase (AMPK), which regulates energy balance. By activating this protein, the researchers aimed to prevent type 2 diabetes and cardiovascular disease.

In the Journals PlusPerspective

Heart failure strongest predictor of poor survival in type 2 diabetes

November 17, 2017
Older adults with type 2 diabetes are at increased risk for death from cardiovascular complications, with the strongest associations found between survival and heart…
Meeting NewsPerspective

Telepharmacy intervention yields modest effect on medication adherence among patients with cardiometabolic diseases

November 15, 2017
ANAHEIM, Calif. — Implementation of a personalized telepharmacy intervention improved medication adherence but did not affect measures of disease control including…
Meeting NewsPerspective

Bariatric surgery an effective strategy to improve BP control in obese hypertensive patients

November 13, 2017
ANAHEIM, Calif. — In the GATEWAY study, obese patients with hypertension were able to reduce their use of antihypertensive drugs while maintaining BP control after…
More Headlines »
CME

Practical Lipidology® Volume 4, Number 1: Focus on LDL Reduction and PCSK9 Inhibition

This activity is supported by an educational grant from Amgen

A preponderance of data shows that low-density lipoprotein cholesterol (LDL-C) plays a causal role in atherosclerotic…
More »
Video
Meeting News

VIDEO: Expert discusses BP management among elderly patients with kidney disease

October 8, 2017
More »
Resource Centers
ObesityWeek

ObesityWeek

CME

Practical Lipidology® (Volume 4): Focus on: LDL Reduction and PCSK9 Inhibition

This activity is supported by an educational grant from Amgen, Inc.

The reduction of low-density lipoprotein cholesterol (LDL-C) is recognized as the primary strategy for decreasing…
More »
Advertisement
Advertisement